Drug Patents owned by Amgen Inc
1. Drug name - CORLANOR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(4 years from now) | |
| CN100402502C | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827600B | AMGEN INC | Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827600A | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827602A | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN200600485I1 | AMGEN INC | Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN200600486I1 | AMGEN INC | Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN269993B | AMGEN INC | Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride |
Feb, 2026
(3 years from now) | |
| IN237447B | AMGEN INC | A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition |
Feb, 2026
(3 years from now) | |
| EP1695965B1 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1707562B1 | AMGEN INC | Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965B9 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1707562A1 | AMGEN INC | Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965A1 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7361650
(Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(3 years from now) | |
|
US7361649
(Pediatric) | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(3 years from now) | |
|
US7879842
(Pediatric) | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Aug, 2026
(3 years from now) | |
|
US7867996
(Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Jun, 2027
(4 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE | TABLET;ORAL | Prescription |
| EQ 7.5MG BASE | TABLET;ORAL | Prescription |
2. Drug name - CORLANOR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7361650 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7361649 | AMGEN INC | β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7879842 | AMGEN INC | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Feb, 2026
(3 years from now) | |
| US7867996 | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Dec, 2026
(4 years from now) | |
| CN100402502C | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827600B | AMGEN INC | Beta-Crystalline Form Of Ivabradine Hydrochloride, Preparation Method Thereof And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827600A | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| CN1827602A | AMGEN INC | Of Ivabradine Hydrochloride Crystal Form, Preparation Method And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN200600485I1 | AMGEN INC | Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparation And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN200600486I1 | AMGEN INC | Crystalline Form Of Ivabradine Hydrochloride, A Process For Its Preparaton And Pharmaceutical Compositions Containing It |
Feb, 2026
(3 years from now) | |
| IN269993B | AMGEN INC | Process For The Preparation Of The ß-Crystalline Form Of Ivabradine Hydrochloride |
Feb, 2026
(3 years from now) | |
| IN237447B | AMGEN INC | A Process For The Preparation Of The Y-Crystalline Form Of Ivabradine Hydtochloride And Its Composition |
Feb, 2026
(3 years from now) | |
| EP1695965B1 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1707562B1 | AMGEN INC | Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965B9 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1707562A1 | AMGEN INC | Crystalline Form Gamma Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| EP1695965A1 | AMGEN INC | Crystalline Form Beta Of The Chlorhydrate Of Ivabradine, Process For Its Preparation And Pharamcetuical Composition Containing It |
Feb, 2026
(3 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 5MG/5ML (1MG/ML) | SOLUTION;ORAL | Prescription |
3. Drug name - LUMAKRAS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10519146 | AMGEN INC | KRAS G12C inhibitors and methods of using the same |
May, 2038
(15 years from now) | |
| US11236091 | AMGEN INC | Solid state forms |
May, 2040
(17 years from now) | |
| EP3630761A1 | AMGEN INC | Kras G12C Inhibitors And Methods Of Using The Same |
May, 2038
(15 years from now) | |
| EP3630761B1 | AMGEN INC | Kras G12C Inhibitors And Methods Of Using The Same |
May, 2038
(15 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 120MG | TABLET;ORAL | Prescription |
4. Drug name - OTEZLA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7893101 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec, 2023
(1 year, 2 months from now) | |
| US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(5 years from now) | |
| CN1965823A | AMGEN INC | (+)-2-(1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl)-4-Acetylamino Isoindoline-1,3-Dione, Synthesis Method And Composition Thereof |
Mar, 2023
(5 months from now) | |
| CN1652772A | AMGEN INC | (+) -2-[1 - (3-Ethoxy - -4 - Methoxyphenyl)--2 - Ethyl]--4--4-Acetylamino--1, 3-Diketone Using The Method And Composition Thereof |
Mar, 2023
(5 months from now) | |
| CN100427085C | AMGEN INC | (+) -2-[1 - (3-Ethoxy - -4 - Methoxyphenyl)--2 - Ethyl]--4--4-Acetylamino--1, 3-Pharmaceutical Use Of Diketone |
Mar, 2023
(5 months from now) | |
| CN1965823B | AMGEN INC | (+) -2-[3 - (1-Ethoxy - -4 - Methoxyphenyl) -2 - Methylsulfonyl-Ethyl] -4 - Stereomeric - -1, 3-Diketone, Its Synthetic Method And Its Composition |
Mar, 2023
(5 months from now) | |
| EP2074995A1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Feb, 2018
(4 years ago) | |
| EP2074995B1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Feb, 2018
(4 years ago) | |
| EP2223687A1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Aug, 2018
(4 years ago) | |
| EP2223687B1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Aug, 2018
(4 years ago) | |
| EP2223688B1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Oct, 2021
(11 months ago) | |
| EP2223688A1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Oct, 2021
(11 months ago) | |
| EP2311453B1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Mar, 2023
(5 months from now) | |
| EP2420490B1 | AMGEN INC | Method For The Preparation Of (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione |
Mar, 2023
(5 months from now) | |
| EP2295055A3 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Mar, 2023
(5 months from now) | |
| EP2295055B1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Mar, 2023
(5 months from now) | |
| EP2311453A1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Mar, 2023
(5 months from now) | |
| EP2295055A2 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Mar, 2023
(5 months from now) | |
| EP1485087A1 | AMGEN INC | (+)-2- [1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione For Use In Treating Psoriasis By Oral Administration |
Mar, 2023
(5 months from now) | |
| EP2420490A1 | AMGEN INC | Method For The Preparation Of (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione |
Mar, 2023
(5 months from now) | |
| EP1485087B1 | AMGEN INC | (+)-2- [1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione For Use In Treating Psoriasis By Oral Administration |
Mar, 2023
(5 months from now) | |
| EP2962690B1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Mar, 2023
(5 months from now) | |
| EP2962690A1 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof |
Mar, 2023
(5 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9724330 | AMGEN INC | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(5 months from now) | |
| US8802717 | AMGEN INC | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(5 months from now) | |
| US7208516 | AMGEN INC | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(5 months from now) | |
| US7659302 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar, 2023
(5 months from now) | |
| US8455536 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(5 months from now) | |
| US9018243 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar, 2023
(5 months from now) | |
| US6962940 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar, 2023
(5 months from now) | |
| US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(11 years from now) | |
| US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(11 years from now) | |
Drugs and Companies using APREMILAST ingredient
Treatment: Use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with active psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriatic arthritis; Use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of psoriasis; use of otezla (apremilast) for the treatment of psoriatic arthritis; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for inhibiting pde4; treatment of adult patients with oral ulcers associated with behcet's disease; treatment of adult patients with active psoriatic arthritis; treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Treatment of psoriatic arthritis using a dosage titration schedule; treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent; Treatment of psoriasis using a dosage titration schedule; treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Prescription |
| 20MG | TABLET;ORAL | Prescription |
| 30MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.